Unique Ingredient Identifier 4VON5FNS3C is listed as a ingredient substance
| RN | 7681-57-4 |
| EC | 231-673-0 |
| NCIT | C77498 |
| RXCUI | 36696 |
| MF | 2Na.O5S2 |
| INCHI KEY | HRZFUMHJMZEROT-UHFFFAOYSA-L |
| SMILES | [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O |
UNII 4VON5FNS3C SODIUM METABISULFITE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| AN,CNBLK INTRATHECAL | INJECTION | NA |
| AN,INFILTRATION | INJECTION | 0.5 % |
| CAUDAL BLOCK | INJECTION | 0.18 % |
| DENTAL | INJECTION | 0.05 % |
| EPIDURAL | INJECTION | 0.18 % |
| IM - IV - SC | INJECTION | 0.15 % |
| IM - IV - SC | SOLUTION, INJECTION | NA |
| INFILTRATION | INJECTION | 0.05 % |
| INHALATION | SOLUTION | 1 % |
| INTRA-ARTICULAR | INJECTION | 0.2 % |
| INTRABURSAL | INJECTION | 0.2 % |
| INTRACARDIAC | INJECTION | 0.09 % |
| INTRACARDIAC | SOLUTION, INJECTION | NA |
| INTRAMUSCULAR | INJECTION | 27.5 %W/V |
| INTRAMUSCULAR | INJECTION | 1.8 MG/1ML |
| INTRAMUSCULAR | SOLUTION, INJECTION | 0.66 %W/V |
| INTRAPERITONEAL | INJECTION | 0.33 % |
| INTRAVENOUS | EMULSION, INJECTION | 0.025 % |
| INTRAVENOUS | INJECTION | 9 MG/1ML |
| INTRAVENOUS | INJECTION | 0.32 % |
| INTRAVENOUS | SOLUTION, INJECTION | 0.66 % |
| INTRAVENOUS INFUSION | INJECTION | 2 mg/1mL |
| IONTOPHORESIS | PATCH, CONTROLLED RELEASE | 0.5 MG |
| IONTOPHORESIS | SOLUTION | 0.05 % |
| IV(INFUSION) | INJECTION | 1.1 % |
| IV(INFUSION) | INJECTION | 1 MG/1ML |
| IV(INFUSION) | SOLUTION, INJECTION | 0.22 % |
| NERVE BLOCK | INJECTION | 0.5 % |
| NERVE BLOCK | SOLUTION, INJECTION | 0.05 % |
| OPHTHALMIC | SOLUTION | 0.25 % |
| OPHTHALMIC | SUSPENSION, DROPS | 0.1 % |
| ORAL | CAPSULE | 0.36 MG |
| ORAL | CONCENTRATE | 2 MG/1ML |
| ORAL | LIQUID | 1 MG/5ML |
| ORAL | ORAL SOLUTION DOSAGE FORM | 1 mg/5mL |
| ORAL | SOLUTION | 320 MG/160ML |
| ORAL | SOLUTION | 5 MG/5ML |
| ORAL | SUSPENSION | 5 MG/5ML |
| ORAL | SUSPENSION, EXTENDED RELEASE | 5 MG/5ML |
| ORAL | SYRUP | 1 MG/1ML |
| ORAL | TABLET | 8 MG |
| PERIDURAL | INJECTION | NA |
| RECTAL | TABLET | 2 MG |
| SUBCUTANEOUS | INJECTION | 1.2 mg/1mL |
| SUBCUTANEOUS | INJECTION | 0.3 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 0.05 % |
| SUBLINGUAL | TABLET | 2 MG |
| SUBMUCOSAL | INJECTION | 0.05 % |
| SUBMUCOSAL | SOLUTION, INJECTION | 5 % |
| TOPICAL | CREAM, AUGMENTED | 0.2 %W/W |
| TOPICAL | EMULSION, CREAM | NA |
| TOPICAL | LOTION | 0.2 %W/V |
| TOPICAL | PATCH | 0.002 MG |
| TOPICAL | PATCH, CONTROLLED RELEASE | 0.5 MG |
| TOPICAL | POWDER, FOR SOLUTION | NA |
| TOPICAL | SUSPENSION | 0.3 %W/W |
| VAGINAL | SPONGE | 1.5 MG |